Hanlin Gao Sells 939 Shares of Fulgent Genetics (NASDAQ:FLGT) Stock

Fulgent Genetics, Inc. (NASDAQ:FLGT) insider Hanlin Gao sold 939 shares of the firm’s stock in a transaction dated Thursday, August 27th. The shares were sold at an average price of $19.91, for a total transaction of $18,695.49. Following the transaction, the insider directly owned 987,790 shares in the company, valued at $19,666,898.90. The trade was a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Hanlin Gao also recently made the following trade(s):

• On Tuesday, June 2nd, Hanlin Gao sold 1,688 shares of Fulgent Genetics stock. The stock was sold at an average price of $17.89, for a total transaction of $30,198.32.

Fulgent Genetics Stock Performance

Shares of FLGT stock opened at $19.61 on Friday. Fulgent Genetics, Inc. has a 52-week low of $13.46 and a 52-week high of $31.04. The company has a 50-day simple moving average of $19.63 and a two-hundred day simple moving average of $18.15. The company has a market capitalization of $539.47 million, a price-to-earnings ratio of -6.95 and a beta of 0.90.

Fulgent Genetics (NASDAQ:FLGT) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.12). Fulgent Genetics had a negative net margin of 26.05% and a negative return on equity of 4.93%. The firm had revenue of $85.39 million during the quarter, compared to analysts’ expectations of $94.00 million. Fulgent Genetics has set its FY 2026 guidance at -2.350–2.220 EPS. On average, sell-side analysts forecast that Fulgent Genetics, Inc. will post -3.48 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Allworth Financial LP purchased a new stake in shares of Fulgent Genetics during the 2nd quarter worth approximately $25,000. Farther Finance Advisors LLC raised its holdings in shares of Fulgent Genetics by 69.3% in the 4th quarter. Farther Finance Advisors LLC now owns 1,339 shares of the company’s stock worth $35,000 after purchasing an additional 548 shares during the period. Kestra Advisory Services LLC purchased a new position in Fulgent Genetics in the fourth quarter valued at approximately $35,000. Legal & General Group Plc purchased a new position in Fulgent Genetics in the second quarter valued at approximately $38,000. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Fulgent Genetics by 214.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,834 shares of the company’s stock valued at $48,000 after purchasing an additional 1,251 shares during the period. 48.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on FLGT. Piper Sandler lifted their price target on Fulgent Genetics from $15.00 to $19.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Weiss Ratings upgraded Fulgent Genetics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Finally, Wall Street Zen raised Fulgent Genetics from a “strong sell” rating to a “sell” rating in a research report on Saturday. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $27.50.

Fulgent Genetics Company Profile

Fulgent Genetics, Inc (NASDAQ: FLGT) is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company’s infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent’s product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.